<DOC>
	<DOCNO>NCT01094158</DOCNO>
	<brief_summary>Primary purpose : Compare change liver triglycerides concentration Aramchol versus placebo arm follow three month treatment . Secondary purpose : Comparing liver enzymes , marker endothelial dysfunction , insulin resistance , SCD1 activity cholesterol synthesis lipid level , Aramchol placebo arm .</brief_summary>
	<brief_title>Study Aramchol Patients With Fatty Liver Disease Nonalcoholic Steatohepatitis</brief_title>
	<detailed_description>A Phase II , multicenter , double blind , randomize , placebo control study effect Aramchol liver triglyceride concentration patient steatosis due NAFLD NASH The purpose study test whether Aramchol reduce safely effectively liver fat concentration patient NAFLD NASH . Aramchol inhibit liver enzyme Stearoyl Coenzyme A Desaturase ( SCD ) . It reduce fatty acid synthesis increase fatty acid oxidation . It show reduce liver fat animal model diet induced Fatty Liver . It also mark hypocholesterolemic effect , mainly via upregulation theABCA1 cholesterol transporter . It thus cause ( incomplete ) SCD inhibition antiatherogenic Primary purpose : Compare change liver triglycerides concentration Aramchol versus placebo arm follow three month treatment . Secondary purpose : Comparing liver enzymes , marker endothelial dysfunction , insulin resistance , SCD1 activity cholesterol synthesis lipid level , Aramchol placebo arm .</detailed_description>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<mesh_term>Cholic Acids</mesh_term>
	<criteria>Patients histologically proven NAFLD NASH base biopsy perform precede 18 month fulfil follow criterion : At least 15 % hepatocytes show steatosis , Fibrosis stage 3 , bridge fibrosis . Patients NAFLD activity score 02 consider NAFLD . Biopsies activity score 3 consider NASH . Triglycerides concentration liver 6 % measure NMRS . At least two elevated serum ALT level previous six month , late test within 2 month trial . Normal slightly impair synthetic liver function ( serum albumin &gt; 3.5gm % , INR 0.81.3 ) Male female age 1875 year . Negative pregnancy test study entry females child bear potential . Females child bear potential practicing reliable contraception throughout study period . Signature write informed consent Evidence cirrhosis liver biopsy . Evidence fibrosis stage 3 liver biopsy . Patient liver disease due acute chronic hepatitis A , B , C , HIV , liver disease affect liver function . Patients cyst , hemangioma , similar abnormality , accept . BMI &gt; 35 &gt; 130 kg body weight Any concomitant , significant : metabolic , infectious , inflammatory , neoplastic , nonliver disease . Various concomitant disease require chronic steroid administration . Use warfarin , metformin , thiaglitazones , insulin current steroid therapy 3 day . Use investigational agent &lt; 30 day prior study . Pregnancy Daily alcohol intake &gt; 10gm/day . Patients symptoms significant mental illness . Inability cooperate communicate investigator , unlikely comply study requirement , unable give inform consent . Performance status : WHO performance status â‰¥4 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>NAFLD</keyword>
	<keyword>NASH</keyword>
	<keyword>Fatty Liver</keyword>
	<keyword>Metabolic Syndrome</keyword>
	<keyword>Endothelial Dysfunction</keyword>
	<keyword>Insulin Resistance</keyword>
	<keyword>Liver Fat</keyword>
</DOC>